Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study

Combination Therapy ◽

Real World ◽

Receptor Agonist ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)

Diabetes ◽

10.2337/db18-1287-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1287-P

Author(s):

MUKUL SINGHAL ◽

HIANGKIAT (JASON) TAN ◽

CRAIG I. COLEMAN ◽

WILLIAM H. HERMAN ◽

JENNIFER CAI ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Real World ◽

Comparative Effectiveness ◽

Receptor Agonist ◽

Treatment Patterns ◽

Glucagon Like Peptide ◽

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients

Diabetes ◽

10.2337/db18-2231-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2231-PUB

Author(s):

SASAN FAZELI ◽

NICOLE EHRHARDT

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients

Diabetes Obesity and Metabolism ◽

10.1111/dom.12089 ◽

2013 ◽

Vol 15 (8) ◽

pp. 770-773 ◽

Cited By ~ 23

Author(s):

N. D. Hopkins ◽

D. J. Cuthbertson ◽

G. J. Kemp ◽

C. Pugh ◽

D. J. Green ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Endothelial Function ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus

Journal of Endocrinological Investigation ◽

10.1007/s40618-019-01153-z ◽

2019 ◽

Vol 43 (5) ◽

pp. 653-662

Author(s):

W. Wang ◽

X. Wen ◽

W. Duan ◽

X. Wang ◽

Y. Chen ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Glucagon Receptor ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Treatment Of Obesity ◽

Long Acting

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Diabetes Therapy ◽

10.1007/s13300-020-00894-y ◽

2020 ◽

Vol 11 (9) ◽

pp. 1965-1982 ◽

Cited By ~ 1

Author(s):

Sanjay Kalra ◽

Rakesh Sahay

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus

Clinical Therapeutics ◽

10.1016/j.clinthera.2016.07.013 ◽

2016 ◽

Vol 38 (10) ◽

pp. e1

Author(s):

Z. Milicevic

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus

Annals of Pharmacotherapy ◽

10.1345/aph.1p047 ◽

2010 ◽

Vol 44 (7-8) ◽

pp. 1294-1300 ◽

Cited By ~ 28

Author(s):

Maria Tzefos ◽

Jacqueline L Olin

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Combination Therapy ◽

Glucagon Like Peptide ◽

Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach

Postgraduate Medicine ◽

10.3810/pgm.2013.05.2666 ◽

2013 ◽

Vol 125 (3) ◽

pp. 112-126 ◽

Cited By ~ 9

Author(s):

Daniel A. Nadeau

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Treatment Strategies ◽

Glucagon Like Peptide ◽

SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus

Journal of the Endocrine Society ◽

10.1210/js.2019-sun-164 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

Author(s):

Sasan Fazeli ◽

Sanjana Rao ◽

Richard Amdur ◽

Nicole Ehrhardt

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Therapeutic Approach ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus

Journal of Clinical Medicine Research ◽

10.14740/jocmr3112w ◽

2017 ◽

Vol 9 (9) ◽

pp. 745-753 ◽

Cited By ~ 10

Author(s):

Kohzo Takebayashi ◽

Toshihiko Inukai

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽